Celularity ( (CELU) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celularity Inc. has filed a Form 12b-25 announcing a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The company says it cannot meet the original deadline for this quarterly filing with the SEC.
Management cites liquidity constraints and limited financial accounting staff as the main reasons for the slowdown in its financial close, reporting process, and preparation of consolidated statements. These operational pressures made a timely Form 10-Q (Quarter Report) filing impractical without unreasonable effort or expense.
Celularity has indicated that it expects to file the delayed Form 10-Q (Quarter Report) within the standard grace period, which is up to five calendar days after the original due date for a quarterly report. The company emphasizes that it is working diligently to complete the report as soon as practicable.
The company does not anticipate any significant change in its results of operations compared with the same quarter a year earlier. Investors should note that any expectations about timing and financial outcomes are forward-looking and subject to change as the close process is finalized.
Celularity highlights its intention to remain in compliance with SEC reporting requirements and to bring its filings up to date promptly. The notification is signed by Acting Chief Financial Officer John Sprague, underscoring executive-level oversight of the delayed Form 10-Q (Quarter Report) and the company’s remediation efforts.
The most recent analyst rating on (CELU) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Neutral.
The score is primarily held down by weak financial performance—continued losses, negative equity, and ongoing cash burn—along with bearish technicals showing a strong downtrend and negative momentum. Valuation support is limited due to negative earnings and no dividend yield data, while the recent licensing transaction is a modest offset that could improve funding and reduce costs if it closes as described.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Average Trading Volume: 198,811
Technical Sentiment Signal: Sell
Current Market Cap: $23.49M
See more insights into CELU stock on TipRanks’ Stock Analysis page.